Genfit has announced encouraging preliminary results from its phase 1b clinical trial evaluating investigational drug GNS561 in combination with a MEK inhibitor (MEKi) in patients with KRAS mutated ...
GRI Bio has announced positive topline results from its phase 2a clinical trial evaluating GRI-0621 in idiopathic pulmonary ...
Johnson & Johnson has reported groundbreaking results from the phase 3 MajesTEC-3 study, highlighting the potential of ...
Modus Therapeutics Holding AB has announced that the first patient has been dosed in part 2 of its ongoing phase 2a clinical study evaluating sevuparin for the treatment of chronic kidney disease (CKD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback